Sentences with phrase «ins by drug companies»

GE's decision, along with new move - ins by drug companies such as Selvita, show the region is becoming an epicenter of the new global life sciences / technology economy, says Mark Stewart, senior vice president and branch manager in the Boston office of real estate services firm Savills Studley.

Not exact matches

Made by companies like Gilead, AbbVie, Merck, and others, drugs that treat the disease are listed at tens of thousands of dollars in the U.S..

That could help curtail a true drug crisis with devastating economic and social impacts — and which was sparked, in large part, by the actions of huge pharmaceutical companies.

WORK undertaken by researchers at the University of Western Australia has contributed to a dramatic rise in interest in a US drug company.

The key is to avoid a company that has only a few drugs in the pipeline that one day may or may not be approved for use by the FDA.

Shares of pioneering CRISPR gene - editing firm Editas fell 7 % in early Tuesday trading after the company announced that it would delay an initial FDA filing for clinical trials of one of its lead drugs, LCA10, to the middle of next year (Editas had originally planned to file by the end of 2017).

Rajiv Malik, president and executive director at EpiPen maker Mylan (essentially the company's number two exec), has been named in a wide - ranging civil suit alleging drug price collusion by numerous prominent generic drug makers.

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

Martin Shkreli, unaffectionately known as the «pharma bro» — and infamous for his decision to hike the list price of Daraprim, a drug used by HIV / AIDS and cancer patients to combat infections, by more than 5,000 % in 2015 under his former company Turing Pharmaceuticals — was convicted on three criminal securities fraud and conspiracy charges by a Brooklyn jury on Friday.

That research will be crucial: An earlier effort by another company, Pathway Genomics, to create a «liquid biopsy» for cancer was greeted in September by a stern letter from the Food and Drug Administration (FDA) warning that the agency had «not found any published evidence that this test or any similar test has been clinically validated as a screening tool for early detection of cancer in high risk individuals.»

Prior to Sucampo, he served as Chief Scientific Officer of Ambrx Inc., a clinical - stage biopharmaceutical company focused on the development of antibody - drug conjugates (ADCs) that was acquired by a consortium led by Fosun Pharmaceutical Group in 2015.

Fortescue Metals Group's Christmas Creek iron ore mine site has been raided for drugs by WA Police, working in cooperation with the company, as part of a crackdown of mine sites across the state.

The company is selling a thing (the kit) by saying it can provide «health reports on 254 diseases and conditions,» including categories such as «carrier status,» «health risks,» and «drug response,» and specifically as a «first step in prevention» that enables users to «take steps toward mitigating serious diseases» such as diabetes, coronary heart disease, and breast cancer...» Most of the uses «listed on your website, a list that has grown over time,» the FDA writes, «are medical device uses [for the] Personal Genome Service.»

Celgene's patents likely won't be challenged by its rivals anytime soon — its three main patents expire in the 2020s, by which point the company will have made a considerable amount of money on the drugs.

The memory - eating disease, expected to afflict 15 million Americans by 2060 (and tens of millions more around the world as life expectancy increases), has no cure; a new drug for the condition hasn't been approved in well over a decade; initially promising experimental treatments seem to be failing with clockwork regularity; and there's not even a definitive consensus on what, exactly, biopharma companies should focus on while developing Alzheimer's medicines.

Since it takes several rounds of discussions to understand something as complicated as drug development, this was a boon to fledgling biopharma companies, and VC funding in the space was booming by 2013.

The article described how an internal investigation conducted by a company executive, Dinesh Thakur, who went on to become a whistleblower, reported appalling deceit: Ranbaxy scientists substituted cheaper, lower - quality ingredients in place of better ingredients, manipulated test parameters, and even bought brand - name drugs and used them in place of their own generics to win FDA approval.

There's been a recent trend in biopharma where some companies, led by Allergan (agn) CEO Brent Saunders» new «social contract» with patients, are voluntarily pledging to limit drug price hikes and being more transparent about which products have seen price increases.

The latest pharma innovation report from Deloitte holds some pretty grim news for pharma: returns on R&D investments by large cap companies slid to a mere 3.7 % in 2016, down from the 10.1 % returns seen in 2010 (although the cost of bringing a drug to market is beginning to stabilize).

The companies have begun to market their «biosimilar» (a generic version of expensive biologic drugs) of Remicade — a copycat of J&J's best - selling rheumatoid arthritis and immunology treatment (which garnered more than $ 5 billion in U.S. sales last year) and was approved by the Food and Drug Administration (FDA) in April — at a striking 35 % discount to its list price.

Crawford's death was confirmed by the Toronto legal firm Osler, Hoskin & Harcourt where Crawford began as a corporate lawyer in the 1950s before leaving to pursue a career with Imasco Ltd., a company that, at the time, owned Imperial Tobacco, Canada Trust and Shoppers Drug Mart.

Solanezumab, a drug developed by Eli Lilly that also acts on the amyloid hypothesis, failed some key clinical trials, though the company is still testing it in the pre-clinical stages of the disease.

By 2013, Bristol's five diabetes drugs were bringing in $ 1.6 billion in sales — not a huge amount, but enough to account for 10 % of the company's revenue.

Early in the decade the company had been dogged by R&D failures, most notably of Vanlev, a high - profile hypertension drug that had been hailed as a can't - miss blockbuster but then fell short of even getting FDA approval.

Drug companies including Purdue Pharma LP and Johnson & Johnson have been fighting lawsuits by two California counties, the city of Chicago, four counties in New York and the state of Mississippi over their opioid marketing practices.

In late December of 2001, ImClone founder and CEO Sam Waksal tipped off family and friends that his company's new cancer drug, Erbitux, was about to be rejected by the FDA.

By bringing a drug that's been well - established as safe in other markets to the U.S. for the first time in order to treat a rare disease, the company doesn't just control its pricing destiny — it will also receive a coveted «priority review voucher» which it can hawk to another firm for tens (or even hundreds) of millions of dollars.

Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol.

CONQUERING FORTRESS BRAIN Personal Wellness Track hosted by Cigna Manchester Room One pharmaceutical company after another has failed in its attempt to develop a drug against Alzheimer's.

Top - selling drugs are ranked based on sales or revenue reported for 2014 by biopharma companies in press announcements, annual reports, investor materials, and / or conference calls.

Similarly, innovation in collaborative, patient - centric drug development models that are being promoted by pharma companies, regulators and patient groups, have the ability to transform the industry and improve productivity significantly.

Not willing to call Twitter's bluff, the city offered a deal to the company, which now works out of space in the gritty but fashionable South of Market district where many Internet start - ups begin: move to a building in the even more gritty and decidedly less fashionable mid-Market neighborhood — on a section of Market Street that is marred by drug dealing, homeless encampments and shuttered storefronts — and get a payroll tax exemption.

Two older mainstays among multiple - sclerosis drugs, made by other companies, have increased prices to seven times their 1990s levels to catch up with the prices of newcomers, researchers reported in April in the journal Neurology.

By adding a health insurance company in the form of Aetna, the resulting combination — retailer, clinic operator, pharmacy benefits manager, and insurer — can realize significant efficiencies, negotiate for lower drug prices with pharmaceutical manufacturers, and capture the growing share of healthcare spend among consumers and employers.

But the company was hit by regulatory and political scrutiny in the past year over its drug pricing and its relationship to a mail - order pharmacy, and its stock took a beating.

COPENHAGEN, April 10 Genmab plans to own a bigger share of drugs in its early - stage pipeline as Europe's biggest biotechnology company prepares to reduce its reliance on a blockbuster cancer drug, marketed by partner Johnson & Johnson.

The talks between CVS and Aetna appear to be in part an attempt to fend off a move by Amazon into the drug - selling business — or at least to insulate the companies in case Amazon does invade.

She co-founded and last served as CEO for Sprout Pharmaceuticals where, in 2015, the company broke through with the first ever FDA - approved drug for low sexual desire in women — dubbed «female Viagra» by the media.

Bayer said in a statement that it doesn't control the cost for patients at the pharmacy, because copays are determined by insurers and pharmacy - benefit managers — an argument that pharmaceuticals companies have long made when facing criticism over drug prices.

He started MSMB Capital, a hedge fund company, in his 20s and drew attention for urging the Food and Drug Administration not to approve certain drugs made by companies whose stock he was shorting.

Rare Daily Staff United Therapeutics is strengthening its arsenal by agreeing to acquire orphan drug company SteadyMed for $ 141 million and up to an additional $ 75 million in a milestone.

In just the past 14 months, drug companies raised the prices of 20 prescription drugs by 200 percent.

The company's overall sales jumped 6 %, led by a ramp up in its Oncology drug Keytruda.

Antares Pharma (ATRS)- The company possesses a strong pipeline of drug / device combination product candidates which provide better treatment options in a variety of disease settings - Xyosted could potentially be approved by September and should see significant adoption due to several advantages over current treatments (keep in mind global male hypogonadism market to exceed $ 3 billion within 10 years).

A federal judge in Delaware on Friday struck down key patents held by Acorda related to Ampyra, opening the doors for generic versions of the drug by companies including Mylan Inc (MYL.O) and Roxane Laboratories Inc..

By August, the company, which sells thousands of drugs and says it fills one in every 13 American prescriptions, was making mea culpas and renewing its promise to «do what's right, not what's easy,» as the company's mission statement goes.

ImmuPharma PLC (LON: IMM), specialist drug discovery and development company, announced that its chairman Tim McCarthy will be presenting at an investor evening hosted by Turner Pope Investments, which acted as agent in the firm's recent # 10mln fundraise.

Before any company can make and market even a generic pharmaceutical drug in the United States, it must be granted a special authorization by the FDA.

Athenex Inc. said Monday it expects its new factory in Dunkirk to be completed by the end of March 2019, but the drug development company's shares tumbled by 5 percent after its fourth - quarter loss was far bigger than analysts expected.

A 2017 investigation into lobbying efforts by «Big Pharma» conducted by The Washington Post and 60 Minutes found that the companies spent more than $ 106 million to lobby Congress in an effort to pass more favorable drug laws.